New Stock News | Sinotau Pharmaceutical Passes HKEX Hearing, Becoming China's First Company to Obtain Marketing Approval for Innovative Radiopharmaceuticals

Zhitong Finance APP has learned that according to the disclosure by the Hong Kong Stock Exchange on October 28, Beijing Sinotau International Pharmaceutical Technology Co., Ltd. (referred to as: Sinotau Pharmaceutical) has passed the listing hearing for the Main Board of the Hong Kong Stock Exchange, with GF Securities, CICC, and CITIC Securities as its joint sponsors. According to a report by China Insights Consultancy, Sinotau Pharmaceutical is the first enterprise in China to (i) obtain marketing approval for innovative radiopharmaceuticals; (ii) obtain production approval for innovative radiopharmaceuticals as an MAH; and (iii) complete registered clinical trials for therapeutic radioligands and have its NDA accepted by the National Medical Products Administration.